Activation of phosphodiesterase IV during desensitization of the A(2A) adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells

Journal of Neurochemistry

Volumn 69, Issue 3, 1997, Pages 1300-1309

  Chang, Yu Hsin ^b   Conti, Marco ^c   Lee, Yi Chao ^a   Lai, Hsing Lin ^a   Ching, Yung Hao ^a   Chern, Yijuang ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Cyclic AMP; Desensitization; Phosphodiesterase IV; Protein kinase A; Receptor

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ADENOSINE A2A RECEPTOR; CYCLIC AMP; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE IV;

ANIMAL CELL; ARTICLE; DESENSITIZATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0030878075     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69031300.x     Document Type: Article

References (32)

1. Alvarez R. and Daniels D. V. (1992) A separation method for the assay of adenylyl cyclase, intracellular cyclic AMP, and cyclic-AMP phosphodiesterase using tritium-labeled substrates. Anal. Biochem. 203, 76-82.
2. Beavo J. A., Conti M., and Heaslip R. J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46, 399-405.
3. Bergstrand H., Kristoffersson J., Lundquist B., and Schurmann A. (1977) Effects of antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate phosphodiesterases. Mol. Pharmacol. 13, 38-43.
4. Bolger G. B., Rodgers L. K., and Riggs M. (1994) Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149, 237-244.
5. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
6. Brooker G., Harper J. F., Terasaki W. I., and Moylan R. D. (1979) Radioimmunoassay of cyclic AMP and cyclic GMP. Adv. Cyclic Nucleotide Res. 10, 2-32.
7. + gene, the structural gene for cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA 86, 3599-3603.
8. Chern Y., King K., Lai H.-L., and Lai H.-T. (1992) Molecular cloning of a novel adenosine receptor gene from rat brain. Biochem. Biophys. Res. Commun. 185, 304-309.
9. 2A adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol. Pharmacol. 44, 950-958.
10. 2A-adenosine receptor-mediated cAMP response: a role for protein phosphatase 2A. Mol. Pharmacol. 48, 1-8.
11. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., and Hidaka H. (1990) Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, H89, of PC12D pheochromocytoma cells. J. Biol. Chem. 265, 5267-5272.
12. Engels P., Fichtel K., and Lubbert H. (1994) Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350, 291-295.
13. Ginty D. D., Glowacka D., DeFranco C., and Wagner J. A. (1991) Nerve growth factor-induced neuronal differentiation after dominant repression of both type I and type II cAMP-dependent protein kinase activities. J. Biol. Chem. 266, 15325-15333.
14. Greenberg M. E., Hermanowski A. L., and Ziff E. B. (1986) Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. Mol. Cell. Biol. 6, 1050-1057.
15. Harlow E. and Lane D. (1988) Antibodies: A Laboratory Manual, pp. 59-137. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
16. Hulley P., Hartikka J., Abde'Al S., Engels P., Buerki H.-R., Wiederhold K.-H., Müller T., Kelly P., Lowe D., and Lübbert H. (1995) Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur. J. Neurosci. 7, 2431-2440.
17. 2 adenosine antagonist in vitro and in vivo. FEBS Lett. 323, 141-144.
18. 2 receptors in rat brain tissue. J. Pharmacol. Exp. Ther. 251, 888-893.
19. Kovala T., Lorimer I. A. J., Blickenden A. M., Ball E. H., and Sanwal B. D. (1994) Protein kinase A regulation of cAMP phosphodiesterase expression in rat skeletal myoblasts. J. Biol. Chem. 269, 8680-8685.
20. Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
21. 2A-adenosine receptor-mediated cAMP response. J. Biol. Chem. 272, 4970-4977.
22. Lugnier C., Stierle A., Beretz A., Schoeffter P., Lebec A., Wermuth C. G., Cazenave J. P., and Stoclet J. C. (1983) Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases: relationship to pharmacological activity. Biochem. Biophys. Res. Commun. 113, 954-959.
23. Monaco L., Vicini E., and Conti M. (1994) Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases. J. Biol. Chem. 269, 347-357.
24. Müller T., Engels P., and Fozard J. R. (1996) Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. Sci. 17, 294-298.
25. Nicholson C. D., Challiss R. A. J., and Shahid M. (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12, 19-27.
26. Olah M. E. and Stiles G. L. (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35, 581-606.
27. Sette C., Iona S., and Conti M. (1994a) The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269, 9245-9252.
28. Sette C., Vicini E., and Conti M. (1994b) The rat PDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269, 18271-18274.
29. Sullivan G. W., Carper H. T., and Mandell G. L. (1995) The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity. Int. J. Immunopharmacol. 17, 793-803.
30. Swinnen J. V., Joseph D. R., and Conti M. (1989) The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. USA 86, 8197-8201.
31. Torphy T. J., Zhou H.-L., Foley J. J., Sarau H. M., Manning C. D., and Barnette M. S. (1995) Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. J. Biol. Chem. 270, 23598-23604.
32. Winer B. (1971) Statistical Principles in Experimental Design. McGraw-Hill, New York.